Halberd News

Press releases and updates on our medical breakthroughs.

Oct 19 2021

Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

By |2021-10-19T20:31:40-04:00October 19th, 2021|Press Releases|Comments Off on Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. ...

Read More
Oct 19 2021

Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

By |2021-10-19T20:41:18-04:00October 19th, 2021|Press Releases|Comments Off on Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, ...

Read More
Oct 12 2021

Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement

By |2021-10-11T21:52:59-04:00October 12th, 2021|Featured, Investor News, News|0 Comments

GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various ...

Read More
Oct 7 2021

Halberd Corporation CEO Letter

By |2021-10-04T21:24:09-04:00October 7th, 2021|Featured, Investor News, News|0 Comments

Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As ...

Read More
Oct 5 2021

Halberd’s VITASHIELDMAX(TM) Immunity Support Product Available on Amazon

By |2021-10-04T20:45:12-04:00October 5th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 5, 2021 – Halberd Corporation (OTC-PINK: "HALB") announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd’s website at www.vitashieldmax.com. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We are pleased that our product will now also be available through ...

Read More
Sep 22 2021

Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement

By |2021-09-21T19:05:47-04:00September 22nd, 2021|Featured, Investor News, News|0 Comments

Agreement To Advance Healthcare Diagnostic Technologies Jackson Center, PA, September 22, 2021 – Halberd Corp. (OTC PINK: HALB) and heliosDx, a wholly owned company of Rush Net, Inc.(OTC PINK: RUSH), an Alpharetta, GA company, announce a Scientific Collaboration Agreement to explore synergies and opportunities mutually beneficial to both companies.  A major objective of the agreement ...

Read More
Sep 13 2021

Halberd’s Treatment Eradicates Primary Building Block of Alzheimer’s Disease

By |2021-09-12T21:20:30-04:00September 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 13, 2021 – Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer’s Disease from test fluids in laboratory testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination ...

Read More
Sep 8 2021

Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions

By |2021-09-07T20:16:32-04:00September 8th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 8, 2021 – Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions.  Mirabelli will be responsible for negotiating joint ventures, license agreements and other activities whereby Halberd can capitalize on his vast experience in pharmaceutical and medical device development and sales. Anthony ...

Read More
Aug 30 2021

Halberd Corporation Alzheimer’s Disease Treatment Tests Yield Outstanding Results

By |2021-08-29T20:56:56-04:00August 30th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 30, 2021 – Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer’s Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU).  Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want ...

Read More
Aug 25 2021

Halberd Receives Patent for Treatment of Cockayne Syndrome — May Provide Pathway to Slow Aging

By |2021-08-24T20:42:26-04:00August 25th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development of the ...

Read More
INVESTOR/MEDIA INQUIRIES

MEDICAL METAVERSE

As part of our efforts to remain at the forefront of breakthrough technologies in the medical and scientific fields, Halberd Corporation is engaged in scientific study and research in the fields of medicine, the prevention, treatment and management of illness and infections and rapid tests to identify infection, and other medical maladies.

To learn more about how we can further your efforts, or to partner with Halberd on specific healthcare solutions, please email: info@halberdcorporation.com

Go to Top